Ellex today announced it had acquired on commercial terms the 20% minority interest in Ellex Australia Pty Ltd hitherto held by a former manager who has retired from the business. The acquisition means that Ellex Australia Pty Ltd is now a wholly-owned subsidiary of Ellex Medical Lasers Limited.

Ellex today announced its financial results for the half-year ended 31 December 2011. Improved sales performance in the Company’s direct markets of America and Australia, combined with continued operating efficiencies, has led to an increase in profit before tax of 50% compared with the prior corresponding period.

Ellex today announced that as a result of improved revenues and operating cost reductions, the Company expects profit before tax for the six months ended 31 December 2011 to be approximately 50% higher than the profit before tax for the prior comparative period.

Ellex is pleased to announce the results of resolutions put to the 2011 Annual General Meeting.

Ellex today announced that it will introduce the innovative Integre Pro™ laser platform for the treatment of retinal disease at the upcoming meeting of the American Academy of Ophthalmology (AAO).

Ellex today advises that Professor John Marshall has resigned as a non-executive director of the Board.

Ellex today announced its unaudited financial results for the full-year ended 30 June 2011. As indicated in the Company’s trading update on 21 July 2011, a material strengthening of the Australian dollar, compounded by costs associated with closure of the Company’s US-based manufacturing facility, negatively impacted earnings and operating performance during the 2011 financial year.

Ellex today announced that as a result of reduced revenues in the 2011 financial year, the Company expects the operating result to be breakeven or a small loss.

Ellex today announced plans to consolidate the manufacture of all Ellex laser and ultrasound products out of its state-of-the-art manufacturing facility in Adelaide, Australia.

Ellex today announced milestone clinical results for its breakthrough Retinal Regeneration Therapy (Ellex 2RT) for the treatment of Early Age-Related Macular Degeneration (AMD).

Ellex today announced the appointment of Tom Spurling as Group CEO, effective immediately. Mr. Spurling will replace outgoing CEO, Simon Luscombe. In parallel with this appointment Yukitaka Isoda has been promoted to the position of President, Global Operations, to support the Company’s global sales and distribution platform.

Ellex today announced that it will introduce a new diagnostic ultrasound mode for its leading Eye Cubed™ system at the upcoming meeting of the American Society of Cataract and Refractive Surgeons Meeting.

Ellex today announced that it will expand its presence into the ophthalmic lens market through a strategic partnership with global lens manufacturer STAAR Surgical.

Ellex today announced its audited financial results for the half-year ended 31 December 2010. Despite achieving improved operating efficiencies during the period, a softening in demand in key markets, compounded by a material strengthening of the Australian dollar, negatively impacted earnings during the first half of the 2011 financial year.

Trading Update: Half-Year Result 2011 Financial Year Ellex today announced that, due to a softening in sales demand and the materially stronger Australian dollar, it expects its profit result for the half-year ending 31 December 2010 to be lower than that achieved in the prior comparable period.

Ellex is pleased to announce the results of resolutions put to the 2010 Annual General Meeting.

Ellex today announced that it will preview a prototype of its new Retinal Regeneration Therapy (Ellex 2RT™) laser at the upcoming Royal Australian and New Zealand College of Ophthalmology (RANZCO) meeting in Adelaide, Australia, from Sunday 21 November.

Ellex today announced that it has secured a second distribution deal with Italian-based CenterVue to market the DRS retinal camera in the United States. This follows the Company’s recent announcement that it had secured distribution rights for CenterVue’s MAIA™ fundus perimetry system in the United States and Australia.

Ellex today announced that it will expand its presence in the ophthalmic diagnostics market through a strategic partnership with leading medical device manufacturer CenterVue SpA.

Ellex announced today a Net Profit Before Tax (NPBT) of $3.6 million for the year ended 30 June 2010, a 16% increase compared to $3.1 million in the previous year.

Ellex announced today a profit upgrade guidance with full year Net Profit Before Tax (NPBT) for 2010 expected to be in the vicinity of $3.5 million, a 13 percent improvement compared to $3.1 million in the previous year, subject to final audit.

Ellex announced today major positive clinical results for its world leading laser Retina Regeneration Therapy (Ellex 2RT™) for the treatment of Age-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR), two conditions that usually result in irreversible blindness for sufferers.

Ellex announced today that initial clinical results of two new studies for Ellex Retina Regeneration Therapy (Ellex 2RT™) will be presented at the Association for Research in Vision and Ophthalmology's (ARVO) 2010 Annual Meeting, which takes place 2-6 May in Fort Lauderdale.

Ellex today announced that it has sublicensed Patent No. 5,549,596, effectively enabling the Company to bring Ellex 2RT(TM) technology to market in the US...

Ellex today announced its audited financial results for the half year ended 31 December 2009. The Company delivered a strong performance during the first half of the 2010 financial year, achieving solid underlying profitability and positive cash flow despite a challenging economic environment.

Ellex today announced that the Company’s earnings performance in the first half of the 2010 financial year was better than anticipated, with unaudited Earnings Before Interest Tax and Depreciation (EBITDA) of $2.9 million, up 12% compared to the period ending December 2008 (excluding the impact of non-recurring items in the comparative period).

Ellex today announced the launch of a new yellow laser photocoagulator, Integre Yellow™, at the 33rd Annual Meeting of the Japanese Society of Ophthalmic Surgeons (JSOS) in Tokyo.

Ellex announced today that world wide sales of the Company's products have softened in the second quarter. As a result, it is expected that the Company's budget targets will not be met for the half year ending on 31 December 2009.

Ellex is pleased to announce the results of resolutions put to the 2009 Annual General Meeting.

Ellex announced today that the Ellex 2RT™ Research Program has been awarded a $0.54 million Victorian Government grant.

Ellex today announced that it has extended its current banking facility with Westpac Banking Corporation. Under the agreement, Ellex has refinanced its core debt facility with Westpac to 30 September 2011.

Ellex today announced that it will introduce the latest version of the Eye Cubed diagnostic ultrasound system at the annual meeting of the American Academy of Ophthalmology (AAO), October 24 – 27, 2009 in San Francisco.

Ellex today announced its financial results for the year ended 30 June 2009.

Ellex today announced that it now has in place more than 1,000 SLT (Selective Laser Trabeculoplasty) laser systems on a global basis.

Ellex today announced that the company’s banker, Westpac, has reviewed Ellex’s financial position and have issued a finance offer along similar lines to the existing arrangements that extends the facility until 31 August 2009, when it will again be reviewed.

Ellex today announced the appointment of John Edwards as General Manager of the Company’s Australian sales subsidiary, Ellex Australia.

Ellex today announced its financial results for the half year ended 31 December 2008. The result demonstrates continued growth in a challenging economic environment.

Ellex announced on the 31 October 2008 that foreign exchange (FOREX) hedging contracts entered into by the Company in July 2008 will impact the profitability of the Company in the current financial year.

Ellex announced today a non-renounceable pro-rata Rights Issue to shareholders of Ellex.

Ellex announced today the results of resolutions put to the 2008 Annual General Meeting.

Ellex today announced the six-month clinical study results for the groundbreaking treatment Retina Regeneration Therapy (Ellex 2RT™) at the annual meeting of the American Academy of Ophthalmology.

Ellex today announced that it will preview a new, multi-color photocoagulation laser, Integre Pro™, at the upcoming American Academy of Ophthalmology (AAO), November 8-11, 2008 in Atlanta.

Ellex announced today that the impact of Foreign Exchange (FOREX) hedging contracts entered into by the Company in July 2008 are likely to temper profits for this financial year

Ellex announced today the appointment of Melanie Young as Chief Financial Officer (CFO), effective immediately. Ellex also announced the appointment of Giuseppe Canala as Company Secretary. These appointments follow the departure of Tony Mitchell.

Ellex announced today the appointment of Mr. Simon Luscombe as Group CEO, effective immediately. This follows the departure of Mr. Kevin McGuinness.

Ellex announced today the appointment of Mr. Giuseppe Canala and Mr. Malcolm Plunkett to its board of directors. Ellex also announced the appointment of Mr. Warwick Kitt as an advisor to the company.

Ellex wishes to advise that it has revised the date for the holding of the 2008 Annual General Meeting.

Ellex wishes to advise that it has received an appropriately authorised Notice of Members’ Resolution under section 249N of the Corporations Act 2001 (Cth) from Intertec Healthcare Partners, L.P. and Dr Matthias Maus giving notice that they propose to move the following motion at the Company’s Annual General Meeting.

Ellex today announced another step in expanding its global reach with the establishment of a direct sales channel in Germany - Ellex Deutschland GmbH.

Ellex today announced its financial results for the year ended 30 June 2008.

Ellex advises today that CEO Mr Peter Falzon has ceased employment with the Company with immediate effect.

Ellex advises today that the Australian Taxation Office (ATO) routine audit of the Company has been completed with no adjustments required.

Ellex announced today that due to the difficult economic environment, sales growth and pre-tax earnings for the 2008 financial year are not expected to be as strong as previously advised.

Ellex announced today the appointment of Tony Mitchell as CFO and company secretary.

Ellex announced today its financial results for the half year ended 31 December, 2007

Ellex announced today that revenue growth in the first half of the 2008 Financial Year would exceed market guidance of 15% over the comparable period in 2007 with approximately 18% achieved.

Ellex announced today the results of resolutions put to the 2007 Annual General Meeting.

Ellex announced today that Warwick Kitt has joined the Board of Ellex Australia Pty Ltd.

Ellex today announced clinical results of an ongoing study for non-thermal Retina Regeneration Therapy (Ellex 2RT™).

Ellex today announced that the initial results of treating patients with Retina Regeneration Therapy (Ellex 2RT™) will be presented by Peter Hamilton MD, FRCOph at the annual meeting of the American Academy of Ophthalmology.

Ellex announced today the appointment of Professor John Marshall and Kevin McGuinness to its board of directors to underpin the growth strategy of the company.

Ellex today announced its financial results for the year ended 30 June 2007.

Ellex announced today that effective September 1, 2007 it has appointed Ms Christin Harris as Vice President of U.S. Sales to lead its sales expansion in the United States.

Ellex announced today that it raised $5.5 million through the placement of 6.5 million ordinary shares at a price of A$0.85 per share.

FDA approval of the 30XL laser slit lamp represents another milestone in Ellex's stated strategy to be the leading brand of lasers to treat glaucoma, cataract and retinal conditions.

Ellex has appointed GT Medical, a division of Guotong Holdings Company Limited as its exclusive distributor in China.

Results confirm that Ellex is gaining market share as a result of investments made in new products and distribution. Revenues grew by 26%, exceeding the estimated market growth rate of 5% per year, to $21.2 million.

Awarded $1.9M AusIndustry Grant to Conduct AMD Laser Research.

Download PDF

Ellex announced today that it has acquired Innovative Imaging, Inc., a profitable U.S.-based leader in the design and manufacture of ophthalmic diagnostic ultrasound systems.

Ellex commences trading of Ellex Australia Pty Ltd as a direct sales subsidiary that will sell the Ellex range of lasers direct to Australian ophthalmologists.

Ellex returns to profitability on the back of strong revenue growth.

Ellex to market its ophthalmic lasers directly to ophthalmologists in Australia, New Zealand and the South Pacific.

Herbert Pummer PhD, an accomplished laser industry veteran, appointed as Vice President of Operations.

Ellex moves to direct sales in US with the appointment of Timothy Broome as Senior Territory Manager.

Kevin McGuinness appointed to the new position of Chief Operating Officer (COO).

Integre Duo, the industry's first solid-state red/green photocoagulator, receives 510(k) clearance.

April 4, 2006, Sydney, Australia

Download PDF

Ellex to introduce the Integre Duo, the world’s first solid-state red and green photocoagulator, today at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in San Francisco.

Global Headquarters, led by CEO, to move to SF Bay Area.

Ellex today reported a Net Profit after Tax of A$1.0 million for the first half of FY06, up significantly on the comparable period last year.

Ellex today announced that the company had signed a contract for the sale of its building in Adelaide for a price of $4.43 million.

Ellex Chairman's Introduction to AGM 2005

AusIndustry has approved an additional grant of $0.4 million

Ellex wishes to advise that it has engaged Knight Frank (Adelaide) to seek expressions of interest for the sale of its head quarters located at 82 Gilbert Street, Adelaide.

Ellex wishes to advise that it has completed a detailed review of the impact of the transition from Australian Accounting Standards to IFRS.

Ellex today announced the Company had achieved a satisfying full year result in line with expectations and has completed a restructuring plan expected to result in strong performance in FY2006.

Ellex Medical announced today that David Lindh had retired from his position as Chairman of the Board of Ellex Medical after 5 years of service and resigned as a Director.

Ellex Medical Lasers Limited (ELX) advises that following the successful conclusion of the development phase for the Solitaire photocoagulator and the introduction into production, engineering and product development will be consolidated back into Adelaide.

Ellex Medical Lasers Limited (Ellex) wishes to advise that Dr Keith Robert Johnson has resigned as a Director of Ellex.

Ellex Medical today announced that it had restructured the senior management team, reflecting the Company's growth strategy, now in it's second year.

Ellex Medical today announced a modest growth in revenues for the six months to December 2004. The Company’s planned strategy of reinvesting into product development and distribution resulted in a modest profit, on a pre-goodwill basis.